Literature DB >> 9506265

Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes.

R Rizzi1, S Bruno, R Dammacco.   

Abstract

Behçet's disease is an immune-mediated vasculitis affecting both small and large vessels. Small-vessel vasculitis is the pathological basis of the multiorgan involvement that results in protean clinical features. However, relapsing aphthous ulcers in the mouth are considered the clinical hallmark and are often also observed over the genitalia. Both manifestations, in association with uveitis, form the typical clinical triad. In addition, skeletal muscles, joints, gastrointestinal, cardiopulmonary, and central nervous systems can be involved. Heterogeneity in incidence, clinical manifestations, course, and severity are observed according to ethnic background. The natural course is chronic with relapses and remissions, gradually abating over the years, but the illness can also be life or sight threatening. Its origin and cause are still obscure: genetic, infectious, environmental, and immunological factors have been proposed. Owing to the lack of a specific test, diagnosis still relies on recognition of the typical clinical pattern. Treatment usually includes corticosteroids and immunosuppressive drugs. A better understanding of the pathogenesis will hopefully improve both diagnosis and therapy. In addition, the development of tests aimed at monitoring disease activity and response to therapy is certainly desirable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9506265     DOI: 10.1007/BF02912462

Source DB:  PubMed          Journal:  Int J Clin Lab Res        ISSN: 0940-5437


  14 in total

Review 1.  Pathogenesis of Adamantiades-Behçet's disease.

Authors:  Christos C Zouboulis; Tobias May
Journal:  Med Microbiol Immunol       Date:  2003-03-05       Impact factor: 3.402

2.  Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet's disease.

Authors:  Leyla Suna Atmaca; F Nilüfer Yalçindağ; Ozden Ozdemir
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-01-17       Impact factor: 3.117

3.  Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet's disease.

Authors:  Lothar Krause; Andreas Altenburg; Nikolaos E Bechrakis; Gregor Willerding; Christos C Zouboulis; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-13       Impact factor: 3.117

4.  Vitrectomy and trabeculectomy combined with interferon alpha treatment in Adamantiades-Behçet's disease: a case report.

Authors:  Lothar Krause; Friedrich Hoffmann; Christos C Zouboulis; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-09-09       Impact factor: 3.117

5.  Soluble endothelial protein C receptor levels in Behçet patients with and without ocular involvement.

Authors:  F Nilüfer Yalçindağ; Figen Batioğlu; Ozden Ozdemir; Esra Cansizoğlu; Yonca Eğin; Nejat Akar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-07-05       Impact factor: 3.117

6.  Amlexanox for the treatment of recurrent aphthous ulcers.

Authors:  Juliette Bell
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 7.  Imaging of systemic vasculitis in childhood.

Authors:  Magdy Soliman; Ronald Laxer; David Manson; Rae Yeung; Andrea S Doria
Journal:  Pediatr Radiol       Date:  2015-07-22

8.  Expression of Pro-inflammatory Protein S100A12 (EN-RAGE) in Behçet's Disease and Its Association with Disease Activity: A Pilot Study.

Authors:  Eun Chun Han; Sung Bin Cho; Keun Jae Ahn; Sang Ho Oh; Jihyun Kim; Dong Soo Kim; Kwang Hoon Lee; Dongsik Bang
Journal:  Ann Dermatol       Date:  2011-08-06       Impact factor: 1.444

Review 9.  Digital ischemia in Behçet's disease: case-based review.

Authors:  Gopika Hari; Nedaa Skeik
Journal:  Rheumatol Int       Date:  2019-10-09       Impact factor: 3.580

10.  Serum levels of soluble P-selectin are increased and associated with disease activity in patients with Behçet's syndrome.

Authors:  Yusuf Turkoz; Cem Evereklioglu; Abdullah Ozkiriş; Selçuk Mistik; Murat Borlu; Ibrahim H Ozerol; Fuat Duygulu; Ozgür Ilhan
Journal:  Mediators Inflamm       Date:  2005-08-31       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.